Trial Profile
Phase I/II study of oral MEK inhibitor selumetinib (AZD6244 hyd-sulphate) in combination with highly active anti retroviral therapy (HAART) in AIDS-associated Kaposi's sarcoma (KS)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Antiretrovirals (Primary) ; Selumetinib (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms SCART
- 18 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 09 Feb 2019 This trial has been completed in United Kingdom.
- 08 Jan 2018 Planned End Date changed from 1 feb 2016 to 1 Jun 2018.